Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-02-09

AUTHORS

Cécile Pautas, Emmanuel Raffoux, Juliette Lambert, Ollivier Legrand, Sylvain Chantepie, Lauris Gastaud, Jean-Pierre Marolleau, Xavier Thomas, Pascal Turlure, Rebecca J. Benner, Erik Vandendries, Karïn Gogat, Hervé Dombret, Sylvie Castaigne

ABSTRACT

The phase 3 ALFA-0701 trial demonstrated improved outcomes with fractionated-dose gemtuzumab ozogamicin (GO) combined with standard chemotherapy vs. standard chemotherapy alone in adults with de novo acute myeloid leukemia (AML). We examined post-transplant outcomes and occurrence of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in patients who received hematopoietic stem cell transplantation (HSCT) as follow-up therapy in ALFA-0701. Patients aged 50–70 years were randomized to standard chemotherapy with or without GO (3 mg/m2 on days 1, 4, and 7 of induction and day 1 on each of two consolidation courses). Allogeneic HSCT was recommended for patients in first complete remission with matched (related or unrelated) donor, except those with core-binding factor AML or normal karyotype and either NPM1+/FLT3-ITDwt or CEBPA+ AML. Eighty-five patients (GO: n = 32; control: n = 53) received HSCT in first complete remission or after relapse/primary induction failure. Three patients (GO: n = 2; control: n = 1 [received GO as follow-up therapy]) developed VOD/SOS after HSCT or conditioning. Post-transplant survival, non-relapse mortality, and relapse were not different between arms. Results indicate fractionated-dose GO as part of induction and consolidation chemotherapy for AML does not induce excess post-transplant VOD/SOS or mortality and thus does not preclude the use of HSCT as consolidation treatment. More... »

PAGES

1474-1477

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/s41409-020-01207-4

DOI

http://dx.doi.org/10.1038/s41409-020-01207-4

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1135279963

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/33564120


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Consolidation Chemotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gemtuzumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hematopoietic Stem Cell Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hepatic Veno-Occlusive Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myeloid, Acute", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nucleophosmin", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Service d\u2019H\u00e9matologie et de th\u00e9rapie cellulaire, H\u00f4pital Henri Mondor, Cr\u00e9teil, France", 
          "id": "http://www.grid.ac/institutes/grid.412116.1", 
          "name": [
            "Service d\u2019H\u00e9matologie et de th\u00e9rapie cellulaire, H\u00f4pital Henri Mondor, Cr\u00e9teil, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pautas", 
        "givenName": "C\u00e9cile", 
        "id": "sg:person.01324451673.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324451673.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Saint-Louis (AP-HP), EA 3518, Universit\u00e9 de Paris, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.413328.f", 
          "name": [
            "H\u00f4pital Saint-Louis (AP-HP), EA 3518, Universit\u00e9 de Paris, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Raffoux", 
        "givenName": "Emmanuel", 
        "id": "sg:person.01241622025.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01241622025.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service d\u2019H\u00e9matologie et Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France", 
          "id": "http://www.grid.ac/institutes/grid.418080.5", 
          "name": [
            "Service d\u2019H\u00e9matologie et Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lambert", 
        "givenName": "Juliette", 
        "id": "sg:person.01365675644.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365675644.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service d\u2019h\u00e9matologie clinique et de th\u00e9rapie cellulaire, H\u00f4pital Saint-Antoine (AP-HP), Universit\u00e9 Paris Pierre et Marie Curie, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.412370.3", 
          "name": [
            "Service d\u2019h\u00e9matologie clinique et de th\u00e9rapie cellulaire, H\u00f4pital Saint-Antoine (AP-HP), Universit\u00e9 Paris Pierre et Marie Curie, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Legrand", 
        "givenName": "Ollivier", 
        "id": "sg:person.0752753564.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752753564.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institut d\u2019H\u00e9matologie de Basse-Normandie, Caen, France", 
          "id": "http://www.grid.ac/institutes/grid.411149.8", 
          "name": [
            "Institut d\u2019H\u00e9matologie de Basse-Normandie, Caen, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chantepie", 
        "givenName": "Sylvain", 
        "id": "sg:person.0716120654.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716120654.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service h\u00e9matologie, Centre Lacassagne, Nice, France", 
          "id": "http://www.grid.ac/institutes/grid.417812.9", 
          "name": [
            "Service h\u00e9matologie, Centre Lacassagne, Nice, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gastaud", 
        "givenName": "Lauris", 
        "id": "sg:person.01210567432.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210567432.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service h\u00e9matologie, CHU Amiens, Amiens, France", 
          "id": "http://www.grid.ac/institutes/grid.134996.0", 
          "name": [
            "Service h\u00e9matologie, CHU Amiens, Amiens, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Marolleau", 
        "givenName": "Jean-Pierre", 
        "id": "sg:person.01226630333.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226630333.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service h\u00e9matologie, Centre Hospitalier Lyon Sud, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.411430.3", 
          "name": [
            "Service h\u00e9matologie, Centre Hospitalier Lyon Sud, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thomas", 
        "givenName": "Xavier", 
        "id": "sg:person.01271000165.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271000165.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service h\u00e9matologie et de th\u00e9rapie cellulaire, CHU de Limoges, Limoges, France", 
          "id": "http://www.grid.ac/institutes/grid.411178.a", 
          "name": [
            "Service h\u00e9matologie et de th\u00e9rapie cellulaire, CHU de Limoges, Limoges, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Turlure", 
        "givenName": "Pascal", 
        "id": "sg:person.01050653075.03", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050653075.03"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Global Product Development, Pfizer Inc, Groton, CT, USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Global Product Development, Pfizer Inc, Groton, CT, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Benner", 
        "givenName": "Rebecca J.", 
        "id": "sg:person.01315444703.64", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315444703.64"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer Inc, Cambridge, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Inc, Cambridge, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vandendries", 
        "givenName": "Erik", 
        "id": "sg:person.01256437330.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256437330.14"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Global Clinical Development, Pfizer Inc, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.476471.7", 
          "name": [
            "Global Clinical Development, Pfizer Inc, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gogat", 
        "givenName": "Kar\u00efn", 
        "id": "sg:person.01255312226.68", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255312226.68"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Saint-Louis (AP-HP), EA 3518, Universit\u00e9 de Paris, Paris, France", 
          "id": "http://www.grid.ac/institutes/grid.413328.f", 
          "name": [
            "H\u00f4pital Saint-Louis (AP-HP), EA 3518, Universit\u00e9 de Paris, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dombret", 
        "givenName": "Herv\u00e9", 
        "id": "sg:person.01036301740.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036301740.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Service d\u2019H\u00e9matologie et Oncologie, Centre Hospitalier de Versailles, Universit\u00e9 de Versailles Saint Quentin, Le Chesnay, France", 
          "id": "http://www.grid.ac/institutes/grid.418080.5", 
          "name": [
            "Service d\u2019H\u00e9matologie et Oncologie, Centre Hospitalier de Versailles, Universit\u00e9 de Versailles Saint Quentin, Le Chesnay, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Castaigne", 
        "givenName": "Sylvie", 
        "id": "sg:person.0770166540.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770166540.76"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/bmt.2016.302", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023654702", 
          "https://doi.org/10.1038/bmt.2016.302"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00277-016-2899-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015754901", 
          "https://doi.org/10.1007/s00277-016-2899-0"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-02-09", 
    "datePublishedReg": "2021-02-09", 
    "description": "The phase 3 ALFA-0701 trial demonstrated improved outcomes with fractionated-dose gemtuzumab ozogamicin (GO) combined with standard chemotherapy vs. standard chemotherapy alone in adults with de novo acute myeloid leukemia (AML). We examined post-transplant outcomes and occurrence of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in patients who received hematopoietic stem cell transplantation (HSCT) as follow-up therapy in ALFA-0701. Patients aged 50\u201370 years were randomized to standard chemotherapy with or without GO (3\u2009mg/m2 on days 1, 4, and 7 of induction and day 1 on each of two consolidation courses). Allogeneic HSCT was recommended for patients in first complete remission with matched (related or unrelated) donor, except those with core-binding factor AML or normal karyotype and either NPM1+/FLT3-ITDwt or CEBPA+ AML. Eighty-five patients (GO: n\u2009=\u200932; control: n\u2009=\u200953) received HSCT in first complete remission or after relapse/primary induction failure. Three patients (GO: n\u2009=\u20092; control: n\u2009=\u20091 [received GO as follow-up therapy]) developed VOD/SOS after HSCT or conditioning. Post-transplant survival, non-relapse mortality, and relapse were not different between arms. Results indicate fractionated-dose GO as part of induction and consolidation chemotherapy for AML does not induce excess post-transplant VOD/SOS or mortality and thus does not preclude the use of HSCT as consolidation treatment.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/s41409-020-01207-4", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1096890", 
        "issn": [
          "0268-3369", 
          "1476-5365"
        ], 
        "name": "Bone Marrow Transplantation", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "56"
      }
    ], 
    "keywords": [
      "hematopoietic stem cell transplantation", 
      "acute myeloid leukemia", 
      "VOD/SOS", 
      "first complete remission", 
      "gemtuzumab ozogamicin", 
      "stem cell transplantation", 
      "standard chemotherapy", 
      "complete remission", 
      "cell transplantation", 
      "myeloid leukemia", 
      "hepatic veno-occlusive disease/sinusoidal obstruction syndrome", 
      "veno-occlusive disease/sinusoidal obstruction syndrome", 
      "allogeneic hematopoietic stem cell transplantation", 
      "de novo acute myeloid leukemia", 
      "use of HSCT", 
      "novo acute myeloid leukemia", 
      "core-binding factor acute myeloid leukemia", 
      "factor acute myeloid leukemia", 
      "primary induction failure", 
      "non-relapse mortality", 
      "post-transplant outcomes", 
      "sinusoidal obstruction syndrome", 
      "post-transplant survival", 
      "part of induction", 
      "consolidation chemotherapy", 
      "obstruction syndrome", 
      "induction failure", 
      "improved outcomes", 
      "chemotherapy", 
      "patients", 
      "consolidation treatment", 
      "normal karyotype", 
      "ozogamicin", 
      "remission", 
      "transplantation", 
      "alfa", 
      "outcomes", 
      "leukemia", 
      "mortality", 
      "relapse", 
      "syndrome", 
      "therapy", 
      "trials", 
      "survival", 
      "adults", 
      "treatment", 
      "induction", 
      "failure", 
      "arm", 
      "years", 
      "karyotype", 
      "donors", 
      "occurrence", 
      "SOS", 
      "conditioning", 
      "use", 
      "results", 
      "part"
    ], 
    "name": "Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia", 
    "pagination": "1474-1477", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1135279963"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/s41409-020-01207-4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "33564120"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/s41409-020-01207-4", 
      "https://app.dimensions.ai/details/publication/pub.1135279963"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-06-01T22:22", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_891.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/s41409-020-01207-4"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41409-020-01207-4'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41409-020-01207-4'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41409-020-01207-4'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41409-020-01207-4'


 

This table displays all metadata directly associated to this object as RDF triples.

285 TRIPLES      22 PREDICATES      94 URIs      84 LITERALS      15 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/s41409-020-01207-4 schema:about N0de4ba45b25e4d53ba311b364db5d01d
2 N136c47c639ab4ed69e599e85af720a0f
3 N70fd96fc60c2461bb12288666137c5ae
4 N7de18342ac2d442fafff86b901ceb558
5 N7eb9d484043a4175a72840f6e2c239e8
6 N9e99e4aa29694b7eb9fbc2f81bc88ad0
7 Ne5617a19383b4638b1dcb4a19e0841d8
8 Nf1e464544c704376a17364cfe596bbeb
9 anzsrc-for:11
10 anzsrc-for:1112
11 schema:author Neb91b96cb52f457598d724a5acbae52f
12 schema:citation sg:pub.10.1007/s00277-016-2899-0
13 sg:pub.10.1038/bmt.2016.302
14 schema:datePublished 2021-02-09
15 schema:datePublishedReg 2021-02-09
16 schema:description The phase 3 ALFA-0701 trial demonstrated improved outcomes with fractionated-dose gemtuzumab ozogamicin (GO) combined with standard chemotherapy vs. standard chemotherapy alone in adults with de novo acute myeloid leukemia (AML). We examined post-transplant outcomes and occurrence of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in patients who received hematopoietic stem cell transplantation (HSCT) as follow-up therapy in ALFA-0701. Patients aged 50–70 years were randomized to standard chemotherapy with or without GO (3 mg/m2 on days 1, 4, and 7 of induction and day 1 on each of two consolidation courses). Allogeneic HSCT was recommended for patients in first complete remission with matched (related or unrelated) donor, except those with core-binding factor AML or normal karyotype and either NPM1+/FLT3-ITDwt or CEBPA+ AML. Eighty-five patients (GO: n = 32; control: n = 53) received HSCT in first complete remission or after relapse/primary induction failure. Three patients (GO: n = 2; control: n = 1 [received GO as follow-up therapy]) developed VOD/SOS after HSCT or conditioning. Post-transplant survival, non-relapse mortality, and relapse were not different between arms. Results indicate fractionated-dose GO as part of induction and consolidation chemotherapy for AML does not induce excess post-transplant VOD/SOS or mortality and thus does not preclude the use of HSCT as consolidation treatment.
17 schema:genre article
18 schema:inLanguage en
19 schema:isAccessibleForFree true
20 schema:isPartOf N757ea00086bc4eb7a6a30003a732c547
21 Ndc8955f3dc474e789a0e04fb485d0085
22 sg:journal.1096890
23 schema:keywords SOS
24 VOD/SOS
25 acute myeloid leukemia
26 adults
27 alfa
28 allogeneic hematopoietic stem cell transplantation
29 arm
30 cell transplantation
31 chemotherapy
32 complete remission
33 conditioning
34 consolidation chemotherapy
35 consolidation treatment
36 core-binding factor acute myeloid leukemia
37 de novo acute myeloid leukemia
38 donors
39 factor acute myeloid leukemia
40 failure
41 first complete remission
42 gemtuzumab ozogamicin
43 hematopoietic stem cell transplantation
44 hepatic veno-occlusive disease/sinusoidal obstruction syndrome
45 improved outcomes
46 induction
47 induction failure
48 karyotype
49 leukemia
50 mortality
51 myeloid leukemia
52 non-relapse mortality
53 normal karyotype
54 novo acute myeloid leukemia
55 obstruction syndrome
56 occurrence
57 outcomes
58 ozogamicin
59 part
60 part of induction
61 patients
62 post-transplant outcomes
63 post-transplant survival
64 primary induction failure
65 relapse
66 remission
67 results
68 sinusoidal obstruction syndrome
69 standard chemotherapy
70 stem cell transplantation
71 survival
72 syndrome
73 therapy
74 transplantation
75 treatment
76 trials
77 use
78 use of HSCT
79 veno-occlusive disease/sinusoidal obstruction syndrome
80 years
81 schema:name Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia
82 schema:pagination 1474-1477
83 schema:productId N0724789b5b964c29906139cc9d091175
84 N1f80d113d654486fb14ac6ca054992b5
85 Na1617ec23d1d434b93c26916ef988b36
86 schema:sameAs https://app.dimensions.ai/details/publication/pub.1135279963
87 https://doi.org/10.1038/s41409-020-01207-4
88 schema:sdDatePublished 2022-06-01T22:22
89 schema:sdLicense https://scigraph.springernature.com/explorer/license/
90 schema:sdPublisher N3da0d5a4eaba4dcd90fe94a1618638dc
91 schema:url https://doi.org/10.1038/s41409-020-01207-4
92 sgo:license sg:explorer/license/
93 sgo:sdDataset articles
94 rdf:type schema:ScholarlyArticle
95 N02e76246f5394adeb80bc3111619265a rdf:first sg:person.0770166540.76
96 rdf:rest rdf:nil
97 N04fc3a5c5e7945a1b9cea3926a440413 rdf:first sg:person.01255312226.68
98 rdf:rest N4be57428f9d243dda3938d8428537176
99 N0724789b5b964c29906139cc9d091175 schema:name doi
100 schema:value 10.1038/s41409-020-01207-4
101 rdf:type schema:PropertyValue
102 N0de4ba45b25e4d53ba311b364db5d01d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Hematopoietic Stem Cell Transplantation
104 rdf:type schema:DefinedTerm
105 N136c47c639ab4ed69e599e85af720a0f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Gemtuzumab
107 rdf:type schema:DefinedTerm
108 N1f80d113d654486fb14ac6ca054992b5 schema:name dimensions_id
109 schema:value pub.1135279963
110 rdf:type schema:PropertyValue
111 N3da0d5a4eaba4dcd90fe94a1618638dc schema:name Springer Nature - SN SciGraph project
112 rdf:type schema:Organization
113 N3f5f05580b8d40e28849e825a1fa923c rdf:first sg:person.01271000165.93
114 rdf:rest N6f66440c0d574dfca4f50a57b2f5219d
115 N4be57428f9d243dda3938d8428537176 rdf:first sg:person.01036301740.76
116 rdf:rest N02e76246f5394adeb80bc3111619265a
117 N6ad0d793370c4329a5ee49f154c18ed8 rdf:first sg:person.01256437330.14
118 rdf:rest N04fc3a5c5e7945a1b9cea3926a440413
119 N6f66440c0d574dfca4f50a57b2f5219d rdf:first sg:person.01050653075.03
120 rdf:rest Nc111a59a17594360bfa4bdd189f1116d
121 N70fd96fc60c2461bb12288666137c5ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Nucleophosmin
123 rdf:type schema:DefinedTerm
124 N757ea00086bc4eb7a6a30003a732c547 schema:volumeNumber 56
125 rdf:type schema:PublicationVolume
126 N7a0ed1ef8d4645bf83389d536a0aadbe rdf:first sg:person.0752753564.08
127 rdf:rest Ndfd0e9ebb1e949e2957e69a569030fb2
128 N7de18342ac2d442fafff86b901ceb558 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Humans
130 rdf:type schema:DefinedTerm
131 N7eb9d484043a4175a72840f6e2c239e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Hepatic Veno-Occlusive Disease
133 rdf:type schema:DefinedTerm
134 N888dcb4708a44af89881df661b6010ba rdf:first sg:person.01365675644.91
135 rdf:rest N7a0ed1ef8d4645bf83389d536a0aadbe
136 N9e99e4aa29694b7eb9fbc2f81bc88ad0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Leukemia, Myeloid, Acute
138 rdf:type schema:DefinedTerm
139 Na1617ec23d1d434b93c26916ef988b36 schema:name pubmed_id
140 schema:value 33564120
141 rdf:type schema:PropertyValue
142 Nc111a59a17594360bfa4bdd189f1116d rdf:first sg:person.01315444703.64
143 rdf:rest N6ad0d793370c4329a5ee49f154c18ed8
144 Nd02c3e4b3356455e911ed54e7aa6bd27 rdf:first sg:person.01210567432.88
145 rdf:rest Ne9ee58211e894666bc67ff0fd8cefe36
146 Ndc8955f3dc474e789a0e04fb485d0085 schema:issueNumber 6
147 rdf:type schema:PublicationIssue
148 Ndfd0e9ebb1e949e2957e69a569030fb2 rdf:first sg:person.0716120654.23
149 rdf:rest Nd02c3e4b3356455e911ed54e7aa6bd27
150 Ne5617a19383b4638b1dcb4a19e0841d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Consolidation Chemotherapy
152 rdf:type schema:DefinedTerm
153 Ne9ee58211e894666bc67ff0fd8cefe36 rdf:first sg:person.01226630333.19
154 rdf:rest N3f5f05580b8d40e28849e825a1fa923c
155 Neb91b96cb52f457598d724a5acbae52f rdf:first sg:person.01324451673.29
156 rdf:rest Nec68e1758e644f42bb5c3eb87c86fb74
157 Nec68e1758e644f42bb5c3eb87c86fb74 rdf:first sg:person.01241622025.01
158 rdf:rest N888dcb4708a44af89881df661b6010ba
159 Nf1e464544c704376a17364cfe596bbeb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Adult
161 rdf:type schema:DefinedTerm
162 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
163 schema:name Medical and Health Sciences
164 rdf:type schema:DefinedTerm
165 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
166 schema:name Oncology and Carcinogenesis
167 rdf:type schema:DefinedTerm
168 sg:journal.1096890 schema:issn 0268-3369
169 1476-5365
170 schema:name Bone Marrow Transplantation
171 schema:publisher Springer Nature
172 rdf:type schema:Periodical
173 sg:person.01036301740.76 schema:affiliation grid-institutes:grid.413328.f
174 schema:familyName Dombret
175 schema:givenName Hervé
176 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036301740.76
177 rdf:type schema:Person
178 sg:person.01050653075.03 schema:affiliation grid-institutes:grid.411178.a
179 schema:familyName Turlure
180 schema:givenName Pascal
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050653075.03
182 rdf:type schema:Person
183 sg:person.01210567432.88 schema:affiliation grid-institutes:grid.417812.9
184 schema:familyName Gastaud
185 schema:givenName Lauris
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210567432.88
187 rdf:type schema:Person
188 sg:person.01226630333.19 schema:affiliation grid-institutes:grid.134996.0
189 schema:familyName Marolleau
190 schema:givenName Jean-Pierre
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226630333.19
192 rdf:type schema:Person
193 sg:person.01241622025.01 schema:affiliation grid-institutes:grid.413328.f
194 schema:familyName Raffoux
195 schema:givenName Emmanuel
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01241622025.01
197 rdf:type schema:Person
198 sg:person.01255312226.68 schema:affiliation grid-institutes:grid.476471.7
199 schema:familyName Gogat
200 schema:givenName Karïn
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255312226.68
202 rdf:type schema:Person
203 sg:person.01256437330.14 schema:affiliation grid-institutes:grid.410513.2
204 schema:familyName Vandendries
205 schema:givenName Erik
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256437330.14
207 rdf:type schema:Person
208 sg:person.01271000165.93 schema:affiliation grid-institutes:grid.411430.3
209 schema:familyName Thomas
210 schema:givenName Xavier
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271000165.93
212 rdf:type schema:Person
213 sg:person.01315444703.64 schema:affiliation grid-institutes:grid.410513.2
214 schema:familyName Benner
215 schema:givenName Rebecca J.
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315444703.64
217 rdf:type schema:Person
218 sg:person.01324451673.29 schema:affiliation grid-institutes:grid.412116.1
219 schema:familyName Pautas
220 schema:givenName Cécile
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324451673.29
222 rdf:type schema:Person
223 sg:person.01365675644.91 schema:affiliation grid-institutes:grid.418080.5
224 schema:familyName Lambert
225 schema:givenName Juliette
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365675644.91
227 rdf:type schema:Person
228 sg:person.0716120654.23 schema:affiliation grid-institutes:grid.411149.8
229 schema:familyName Chantepie
230 schema:givenName Sylvain
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716120654.23
232 rdf:type schema:Person
233 sg:person.0752753564.08 schema:affiliation grid-institutes:grid.412370.3
234 schema:familyName Legrand
235 schema:givenName Ollivier
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752753564.08
237 rdf:type schema:Person
238 sg:person.0770166540.76 schema:affiliation grid-institutes:grid.418080.5
239 schema:familyName Castaigne
240 schema:givenName Sylvie
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770166540.76
242 rdf:type schema:Person
243 sg:pub.10.1007/s00277-016-2899-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015754901
244 https://doi.org/10.1007/s00277-016-2899-0
245 rdf:type schema:CreativeWork
246 sg:pub.10.1038/bmt.2016.302 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023654702
247 https://doi.org/10.1038/bmt.2016.302
248 rdf:type schema:CreativeWork
249 grid-institutes:grid.134996.0 schema:alternateName Service hématologie, CHU Amiens, Amiens, France
250 schema:name Service hématologie, CHU Amiens, Amiens, France
251 rdf:type schema:Organization
252 grid-institutes:grid.410513.2 schema:alternateName Global Product Development, Pfizer Inc, Groton, CT, USA
253 Pfizer Inc, Cambridge, MA, USA
254 schema:name Global Product Development, Pfizer Inc, Groton, CT, USA
255 Pfizer Inc, Cambridge, MA, USA
256 rdf:type schema:Organization
257 grid-institutes:grid.411149.8 schema:alternateName Institut d’Hématologie de Basse-Normandie, Caen, France
258 schema:name Institut d’Hématologie de Basse-Normandie, Caen, France
259 rdf:type schema:Organization
260 grid-institutes:grid.411178.a schema:alternateName Service hématologie et de thérapie cellulaire, CHU de Limoges, Limoges, France
261 schema:name Service hématologie et de thérapie cellulaire, CHU de Limoges, Limoges, France
262 rdf:type schema:Organization
263 grid-institutes:grid.411430.3 schema:alternateName Service hématologie, Centre Hospitalier Lyon Sud, Lyon, France
264 schema:name Service hématologie, Centre Hospitalier Lyon Sud, Lyon, France
265 rdf:type schema:Organization
266 grid-institutes:grid.412116.1 schema:alternateName Service d’Hématologie et de thérapie cellulaire, Hôpital Henri Mondor, Créteil, France
267 schema:name Service d’Hématologie et de thérapie cellulaire, Hôpital Henri Mondor, Créteil, France
268 rdf:type schema:Organization
269 grid-institutes:grid.412370.3 schema:alternateName Service d’hématologie clinique et de thérapie cellulaire, Hôpital Saint-Antoine (AP-HP), Université Paris Pierre et Marie Curie, Paris, France
270 schema:name Service d’hématologie clinique et de thérapie cellulaire, Hôpital Saint-Antoine (AP-HP), Université Paris Pierre et Marie Curie, Paris, France
271 rdf:type schema:Organization
272 grid-institutes:grid.413328.f schema:alternateName Hôpital Saint-Louis (AP-HP), EA 3518, Université de Paris, Paris, France
273 schema:name Hôpital Saint-Louis (AP-HP), EA 3518, Université de Paris, Paris, France
274 rdf:type schema:Organization
275 grid-institutes:grid.417812.9 schema:alternateName Service hématologie, Centre Lacassagne, Nice, France
276 schema:name Service hématologie, Centre Lacassagne, Nice, France
277 rdf:type schema:Organization
278 grid-institutes:grid.418080.5 schema:alternateName Service d’Hématologie et Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France
279 Service d’Hématologie et Oncologie, Centre Hospitalier de Versailles, Université de Versailles Saint Quentin, Le Chesnay, France
280 schema:name Service d’Hématologie et Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France
281 Service d’Hématologie et Oncologie, Centre Hospitalier de Versailles, Université de Versailles Saint Quentin, Le Chesnay, France
282 rdf:type schema:Organization
283 grid-institutes:grid.476471.7 schema:alternateName Global Clinical Development, Pfizer Inc, Paris, France
284 schema:name Global Clinical Development, Pfizer Inc, Paris, France
285 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...